OTCMKTS:HKMPF Hikma Pharmaceuticals (HKMPF) Stock Price, News & Analysis $27.73 0.00 (0.00%) As of 05/23/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendHeadlinesShort InterestBuy This Stock About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hikma Pharmaceuticals alerts:Sign Up Key Stats Today's Range$27.73▼$27.7350-Day Range$26.20▼$27.7352-Week Range$22.56▼$28.92VolumeN/AAverage Volume1,600 shsMarket Capitalization$6.15 billionP/E RatioN/ADividend Yield3.46%Price TargetN/AConsensus RatingStrong Buy Company OverviewHikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.Read More… Receive HKMPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HKMPF Stock News HeadlinesBio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA ® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA ® (ustekinumab) InjectionMay 27 at 2:17 AM | investing.comAFT Pharmaceuticals Expands US Maxigesic Partnership with HikmaMay 25 at 10:29 PM | tipranks.comF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLaren Engineering, a NASDAQ-listed marine tech company unveiled a groundbreaking new electric powertrain set to transform the industry.May 28, 2025 | The Tomorrow Investor (Ad)Hikma Pharmaceuticals Executives Involved in Share Pledge TransactionsMay 20, 2025 | tipranks.comHikma Pharmaceuticals Executives Acquire Shares Under DRIPMay 8, 2025 | tipranks.comHikma Pharmaceuticals Announces Managerial Share TransactionsApril 30, 2025 | tipranks.comHikma Pharmaceuticals Successfully Concludes 2025 AGM with All Resolutions PassedApril 24, 2025 | tipranks.comPromising Financial Outlook and Strategic Positioning of Hikma Pharmaceuticals: A Buy Recommendation by Christian GlennieApril 24, 2025 | tipranks.comSee More Headlines HKMPF Stock Analysis - Frequently Asked Questions How have HKMPF shares performed this year? Hikma Pharmaceuticals' stock was trading at $24.12 at the beginning of 2025. Since then, HKMPF shares have increased by 15.0% and is now trading at $27.7301. View the best growth stocks for 2025 here. How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Record date for 5/1 Dividend3/21/2025Ex-Dividend for 5/1 Dividend3/21/2025Dividend Payable5/01/2025Today5/28/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:HKMPF Previous SymbolOTC:HKMPF CIKN/A Webwww.hikma.com Phone442073992760Fax44-20-7399-2761Employees9,100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.46 Current Ratio1.66 Quick Ratio0.98 Sales & Book Value Annual Sales$2.88 billion Price / Sales2.14 Cash Flow$3.28 per share Price / Cash Flow8.46 Book Value$10.03 per share Price / Book2.76Miscellaneous Outstanding Shares221,886,000Free FloatN/AMarket Cap$6.15 billion OptionableNot Optionable Beta0.57 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:HKMPF) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredDollar Collapse Warning: Protect Your Wealth NOWGlobal central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.